DexCom (DXCM) Q1 2026 Earnings Transcript

DexCom reported Q1 revenue of $1.19 billion, up 15% reported and 12% organic, with gross margin expanding to 63.5% from 57.5% and operating income rising to $264.4 million from $143.1 million. Management reaffirmed full-year revenue guidance of $5.16 billion-$5.20 billion while raising non-GAAP operating margin guidance to 23%-23.5% and EBITDA margin guidance to 31%-31.5%. The call highlighted strong adoption of the G7 15-day system, a new Prime Therapeutics coverage win that expands the covered type 2 non-insulin population to over 7 million lives by year-end, and upcoming catalysts including the ADA readout for the non-insulin RCT and the Stello redesign.

Analysis

DXCM is shifting from a reimbursement story to a utilization story. The key second-order effect is that coverage wins are no longer just expanding the addressable base; they are increasing physician comfort in writing broadly, which should improve script velocity even before CMS acts. That matters because the company’s growth algorithm is increasingly self-reinforcing: better product performance lifts NPS, higher NPS supports retention, and better retention lowers the effective CAC required to monetize each newly covered life.

The market may be underestimating how much of the 2026 upside is already embedded in the current guide. Management is signaling that gross margin can re-rate once oil-linked inputs normalize, while operating leverage is being amplified by software/service improvements and a more efficient field force. The more important catalyst is ADA: if the type 2 non-insulin RCT is clean and statistically convincing, it should compress the timeline for payer expansion outside the U.S. and could pull forward investor confidence on the 2027–2028 growth runway.

The main bear case is not demand; it is timing and mix. A 50–100 bp input-cost hit is manageable, but if freight, resins, or geopolitical shipping issues persist, margins may look like they are stagnating just as revenue accelerates, creating a valuation gap between top-line momentum and near-term EPS optics. The contrarian view is that the stock may be too focused on the next quarter’s U.S. script cadence and not enough on the durable operating system DXCM is building: broader coverage, higher conversion, and multiple new product vectors that can extend share gains for several years.

Key Decisions for Investors

• Go long DXCM into ADA (1–4 week horizon) via stock or call spreads; catalyst asymmetry is favorable if the non-insulin RCT validates payer-level outcomes and reframes the market from 'coverage optional' to 'coverage inevitable'.
• Pair trade: long DXCM / short a slower-growth diabetes-care peer with weaker coverage momentum over 1–3 months; DXCM has both higher near-term catalyst density and better self-help on margin.
• Buy DXCM on any post-earnings pullback tied to gross-margin anxiety; the current guide appears to underwrite the oil/resin headwind conservatively, so downside should be bounded unless logistics worsen materially.
• For hedged exposure, consider a bullish call spread rather than outright long; the setup has strong upside into ADA and Investor Day, but headline risk around CMS timing can keep implied volatility elevated.
• If the stock rerates sharply ahead of ADA, trim into strength and keep a smaller core position for the 6–12 month coverage-expansion thesis, which looks more durable than the market is pricing.